IBA qualifies as the only supplier for second round of tender to provide ten proton therapy units across Spain
26 Août 2022 - 7:00AM
IBA qualifies as the only supplier for second round of tender to
provide ten proton therapy units across
Spain
Louvain-La-Neuve, Belgium, 26 August,
2022 – IBA (Ion Beam Applications S.A.,
EURONEXT), the world leader in particle accelerator technology and
the world’s leading provider of proton therapy solutions for the
treatment of cancer, today announces that the Company is the only
proton therapy equipment supplier that has qualified for the second
round of a significant public tender launched by the Spanish
Ministry of Health. This public tender is aimed at selecting one or
several proton therapy suppliers to install 10 proton therapy units
across the country.
The Spanish Ministry of Health has published the
results of the first round of selection of the proton therapy
public tender with IBA being the only vendor fulfilling all the
criteria. Therefore, IBA has qualified for the second round, with
three rounds in total.
In 2021, the Ministry of Health and the Amancio
Ortega Foundation, signed an agreement under which the Foundation
agreed to donate up to EUR 280 million to the Ministry of Health
for the purchase of 10 proton therapy units to be installed across
the country. The public tender, launched in July 2022, includes
three selection rounds to choose the companies eligible to provide
proton therapy equipment to the Spain National Health System.
Olivier Legrain, Chief Executive Officer
at IBA, commented: “We are excited to be the sole vendor
that has qualified for the next round of this important tender. The
scale of the project highlights the ongoing growth of the proton
therapy market in Europe and more broadly. As the global market
leader in proton therapy solutions, IBA is well positioned to
support the Spanish Ministry of Health to bring this highly
targeted cancer treatment to more patients in Spain.”
***ENDS***
About IBA
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA is also a leading player in the areas
of industrial sterilization, radiopharmaceuticals, and dosimetry.
Based in Louvain-la-Neuve, Belgium, the company employs
approximately 1,600 people worldwide. IBA is a certified B
Corporation (B Corp) meeting the highest verified social and
environmental performance standards.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com
###
CONTACTSIBASoumya
ChandramouliChief Financial Officer+32 10
475 890Investorrelations@iba-group.com
Olivier LechienCorporate
Communication Director+32 10 475 890communication@iba-group.com
Consilium Strategic
CommunicationsAmber Fennell, Angela Gray, Lucy
Featherstone+44 (0) 20 3709 5700IBA@consilium-comms.com
- 20220826-IBA-Proton-therapy-Tender-Spain-EN
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024